Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 27, 2022

SELL
$10.83 - $18.41 $498,905 - $848,093
-46,067 Closed
0 $0
Q3 2021

Oct 27, 2021

BUY
$13.07 - $18.84 $1,307 - $1,884
100 Added 0.22%
46,067 $827,000
Q2 2021

Jul 27, 2021

SELL
$16.52 - $20.4 $355,180 - $438,599
-21,500 Reduced 31.87%
45,967 $789,000
Q1 2021

May 03, 2021

BUY
$16.56 - $25.46 $34,776 - $53,466
2,100 Added 3.21%
67,467 $1.35 Million
Q4 2020

Feb 01, 2021

BUY
$15.77 - $19.03 $3,154 - $3,806
200 Added 0.31%
65,367 $1.11 Million
Q3 2020

Oct 26, 2020

BUY
$16.59 - $24.79 $6,636 - $9,916
400 Added 0.62%
65,167 $1.08 Million
Q2 2020

Jul 29, 2020

BUY
$16.86 - $23.44 $269,203 - $374,266
15,967 Added 32.72%
64,767 $1.5 Million
Q1 2020

May 01, 2020

BUY
$14.47 - $27.96 $693,532 - $1.34 Million
47,929 Added 5502.76%
48,800 $871,000
Q1 2020

Apr 28, 2020

SELL
$14.47 - $27.96 $736,942 - $1.42 Million
-50,929 Reduced 98.32%
871 $15,000
Q4 2019

Jan 24, 2020

BUY
$15.87 - $23.12 $153,939 - $224,264
9,700 Added 23.04%
51,800 $1.12 Million
Q3 2019

Oct 22, 2019

BUY
$16.91 - $36.27 $6,764 - $14,508
400 Added 0.96%
42,100 $767,000
Q2 2019

Jul 26, 2019

SELL
$31.0 - $36.3 $263,500 - $308,550
-8,500 Reduced 16.93%
41,700 $1.48 Million
Q1 2019

May 06, 2019

BUY
$31.58 - $46.35 $18,948 - $27,810
600 Added 1.21%
50,200 $1.69 Million
Q4 2018

Feb 01, 2019

SELL
$30.43 - $56.65 $54,774 - $101,970
-1,800 Reduced 3.5%
49,600 $1.63 Million
Q3 2018

Oct 26, 2018

BUY
$46.46 - $68.49 $171,902 - $253,412
3,700 Added 7.76%
51,400 $3.13 Million
Q2 2018

Aug 08, 2018

BUY
$46.25 - $104.45 $13,875 - $31,335
300 Added 0.63%
47,700 $2.33 Million
Q1 2018

May 08, 2018

BUY
$57.4 - $108.44 $2.72 Million - $5.14 Million
47,400 New
47,400 $5.04 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $184M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track State Of Michigan Retirement System Portfolio

Follow State Of Michigan Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Michigan Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on State Of Michigan Retirement System with notifications on news.